Molotinib original manufacturer

The original manufacturer of molotinib isGSK (GSK). Molotinib, known as momelotinib in English, is an innovative drug mainly used to treat moderate or high-risk myelofibrosis, including primary and secondary types, especially for patients with anemia symptoms. This drug is the first and only treatment available for patients with myelofibrosis and anemia. After rigorous phase 3 clinical trials, such as MOMENTUM and SIMPLIFY-1, molotinib has demonstrated significant efficacy, better improving patients' anemia symptoms and reducing the need for blood transfusions compared with control drugs. It should be noted that molotinib is a prescription drug, and patients should strictly follow the doctor's instructions when using it to ensure safety and effectiveness. If you have any medication issues, please communicate with your attending doctor in a timely manner.